Year: 2024
Type: article
Abstract: TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market.
Source: Vaccines
Institutions: European Vaccine Initiative, Biomedical Primate Research Centre, Fraunhofer Institute for Molecular Biology and Applied Ecology, Helmholtz Centre for Infection Research, Instituto de Biologia Experimental e Tecnológica, Intravacc (Netherlands), Universitat Autònoma de Barcelona, Centre de Recerca en Sanitat Animal, Animal Health Research Center, London School of Hygiene & Tropical Medicine, Medicines and Healthcare products Regulatory Agency, Statens Serum Institut, Vaccine Formulation Institute
Language: English
Subfield: Information Systems and Management
Field: Decision Sciences
Domain: Social Sciences
Open Access status: gold
Estimated APC paid: $3,069
OpenAlex ID: W4405699454